IDEAYA Biosciences Interim IDE397 Phase 1 Clinical Data and Q1 2022 Corporate Update

17 Corporate Update Darovasertib Phase 2 Clinical and Preclinical PARG, Pol Theta and WRN Programs Maturing • Darovasertib (PKC) GNAQ/11, CMET Tumors Daro + Crizotinib (cMETI) - Ph2 in MUM Metastatic Uveal Melanoma GNAQ/11 Skin Melanoma Daro Monotherapy - Ph 1 (IST) Primary Adjuvant UM Expansion Opportunities - Preclinical Daro + KRASi in KRAS Tumors Daro + Crizo in cMET Tumors Key Updates Daro + Crizo clinical data presented December 2021 showed robust clinical activity with manageable side effect profile in MUM, including 100% DCR (n=16) Expanded relationship with Pfizer under clinical collaboration and supply agreements in support of potential registrational trial in MUM, subject to FDA feedback, and of evaluation in cMET driven tumors Targeting FDA guidance and clinical data update in MUM mid-2022, including tolerability, clinical efficacy (1) IDEAYA Earnings Release issued March 15, 2022 (2) Includes cash, cash equivalents and marketable securities as of December 31, 2022 IDE161 (PARG) HRD / BRCA IDE161 Development Candidate Key Updates Observed in vivo efficacy with enhanced TGI or tumor regressions in niraparib-resistant models Exercised option for an exclusive worldwide license from CRUK and University of Manchester Targeting IND submission Q4 2022 Werner Helicase MSI-High WRN Helicase Inhibitor - Lead Series Key Updates Targeting Development Candidate 2023 Potential for up to $20 million in aggregate milestone payments from GSK for preclinical to early Phase 1 Pol Theta HRD / BRCA Pol Theta Inhibitor - Candidate Selection Key Updates Demonstrated in vivo efficacy in BRCA2 xenograft model in combination with niraparib, a PARPI IND enabling studies H1 2022 Potential for up to $20 million aggregate milestone payments from GSK for preclinical to early Phase 1 Financial Results Fourth Quarter and Full Year 2021 Key Updates Strong Balance Sheet with ~$368 M in Cash 1,2 Anticipated to fund planned operations into 2025 Operating Expenses ~$21 M Q4 and ~$78 M Full Year IDEAVA BIOSCIENCES

View entire presentation